XORTX Therapeutics Inc

Market Cap

$4M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.06-$0.79 (-27.72%)

Jun 22, 2026

52W High $5.5052W Low $1.73

Company Details

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treat...

Leadership

Allen Warren Davidoff Ph.D.Founder

Founder, CEO, President & Director

Michael Scott Bumby D.V.M., M.B.A.

Chief Financial Officer

Stephen Haworth M.D., MRCP

Chief Medical Officer

Stacy Evans M.B.A., M.D.

Chief Business Officer

Nick Rigopulos

Director of Communications

David Sans M.B.A., Ph.D.

Director of Corporate Development

David MacDonald Ph.D.

Consultant of Clinical Operations

Charlotte May

Corporate Secretary

IPO Date

Nov 28, 2018

Website

www.xortx.com

Key Metrics TTM (CAD)

Revenue

- YoY

Net Income

-3M

EPS (Diluted)

Free Cash Flow

-3M

Revenue / Share

0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability (CAD)

Operating Cash Flow (CAD)

CapEx Spend (CAD)

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation (CAD)

OpEx Breakdown (CAD)

War Chest (CAD)

Shares Outstanding